Solventum (SOLV)

Health Care · $15.3B market cap · SEC CIK 0001964738

Next reports on Feb 24, 2027, before the open, with analysts expecting $1.82 in earnings per share.

52-week range $62.38 to $94.16. 4% below its 52-week high and 44% above its low.

The case for SOLV

• Gross margin of 55% absorbs cost shocks.
• Moves less than the market (beta 0.73).

The case against

• Expensive for its growth: 97.8× earnings, where 0% a year of growth would justify about 8×.
• Burned $10.0M of free cash in FY2025.
• Earnings per share down 89.7%.
• Long-term debt of $5.0B would take 14 years of operating cash flow to repay.
• Revenue slipped 2.8% on the year.
• Return on equity of only 3%.

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from Solventum's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What Solventum says it does

Solventum Corporation ("Solventum," "we," "our," "us," or the "Company"), is a leading global healthcare company developing, manufacturing, and commercializing a broad portfolio of solutions that leverages deep material science, data science, and digital capabilities to address critical customer and patient needs. We constantly seek to enable the improvement of standards of care and move healthcare forward with innovation powered by insights, clinical intelligence, technology, and manufacturing expertise. Our 70+ year history of discovering and innovating advanced solutions has helped us solve our customers’ toughest challenges. Our solutions are relied on every day within the global healthcare industry to deliver higher-quality patient care, more efficient processes and workflows, and improved standards of safety and accuracy. Additionally, our products and services are present along a patient’s journey through prevention, diagnosis,…

Risk factors SOLV lists in its 10-K

• Solventum may not achieve some or all of the expected benefits of the Spin-Off
• In connection with the Spin-Off, Solventum incurred debt obligations and may incur additional obligations in the future, which could adversely affect its business and profitability and its ability to meet other obligations
• Solventum may not be able to engage in desirable capital-raising or strategic transactions following the Spin-Off
• obtained, Solventum may not be entitled to the full benefit of such contracts, permits and other assets and rights, which could increase its expenses or otherwise harm its business and financial performance
• Following the Spin-Off, Solventum’s commercial relationships with 3M remain significant, which could adversely affect Solventum’s business, its ability to meet other obligations and the market price of its common stock
• Solventum’s results may be impacted by the effects of, and changes in, worldwide economic, political, regulatory, international trade and geopolitical conditions, war and other events beyond its control
• The deployment and use of artificial intelligence (
• Public health crises may increase Solventum’s cost of doing business and disrupt Solventum’s operations
• Our brands are critical to our success, and damage to our reputation or our brands could adversely affect our business, results of operations or financial condition
• Solventum may not be able to effectively integrate acquired businesses into its operations or achieve expected cost savings or profitability from its acquisitions
• Solventum’s restructuring program may not be successful or Solventum may not fully realize the expected cost savings and/or operating efficiencies from its restructuring initiatives
• Solventum may not be able to access the capital and credit markets on terms that are favorable to Solventum, or at all
• Change in Solventum’s credit ratings could increase cost of funding
• Foreign currency exchange rates and fluctuations in those rates may affect Solventum’s ability to realize projected growth rates in its sales and earnings
• Changes in interest rates could adversely affect Solventum
• Solventum operates in highly competitive markets, competition may increase in the future and the healthcare industry may be disrupted, necessitating that Solventum lower prices or resulting in a loss of market share
• Consolidation in the healthcare industry could have an adverse effect on Solventum’s revenues and results of operations
• Reductions in customers’ research budgets or government funding may adversely affect Solventum’s business
• The success of many of Solventum’s products depends upon certain key healthcare professionals
• Changes in reimbursement practices of third-party payers or other cost containment measures or worsening economic conditions could affect the demand for Solventum’s products and the prices at which they are sold
• 3M is the sole source of supply for raw materials used in certain of our products and our business will be harmed if 3M does not satisfy our requirements
• Solventum may face potential liabilities related to PFAS, which could adversely impact Solventum’s results
• Climate change and the impacts of climate change may materially adversely affect Solventum’s business, results of operations, financial condition and cash flows
• Solventum operates in a strictly regulated industry, and compliance with laws and regulations applicable to the commercialization of Solventum’s products is costly and failure to comply may result in significant penalties
• Solventum is subject to laws and regulations governing government contracts, public procurement and government reimbursements in many jurisdictions, as to which the failure to comply could adversely affect Solventum’s business
• Solventum may be unable to obtain, maintain, protect or effectively enforce its intellectual property rights
• Changes in tax rates, laws or regulations could adversely impact Solventum’s financial results
• Solventum’s tax burden could increase as a result of ongoing or future tax audits and inquiries
• Solventum could be negatively impacted by future changes in the allocation of income to each of the income tax jurisdictions in which Solventum operates
• If Solventum is unable to attract or retain key personnel and qualified employees, or maintain relations with its employees, unions and other employee representatives, Solventum’s business would be adversely affected
• A significant number of shares of Solventum common stock may be sold by 3M or others, which may cause the Solventum stock price to decline
• Anti-takeover provisions could enable Solventum’s Board of Directors to resist a takeover attempt by a third party and limit the power of its shareholders

Filings

Other Health Care companies